Cover Story
Free
By Alexandria Carolan
A sense of foreboding descended on Narjust Duma as she sat at a presentation on drug-induced toxicities. The year was 2018, Duma was a 31-year-old second-year fellow at Mayo Clinic, and her discomfort stemmed from something other than the subject matter discussed.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - How the 2024 elections can impact cancer policy
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation